Journal
FRONTIERS IN PHARMACOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2020.615211
Keywords
in-crystal fragment screening; CR3022; drug discovery; PPI inhibitors; SARC-CoV-2-RBD
Categories
Funding
- British Heart Foundation [FS/14/29/30896]
- Medical Research Council [MC_PC_17164]
- BBSRC [BB/T002212/1] Funding Source: UKRI
- MRC [MC_PC_17164] Funding Source: UKRI
Ask authors/readers for more resources
In-crystal fragment screening is a powerful tool to chemically probe the surfaces used by proteins to interact, and identify the chemical space worth exploring to design protein-protein inhibitors. A crucial prerequisite is the identification of a crystal form where the target area is exposed and accessible to be probed by fragments. Here we report a crystal form of the SARS-CoV-2 Receptor Binding Domain in complex with the CR3022 antibody where the ACE2 binding site on the Receptor Binding Domain is exposed and accessible. This crystal form of the complex is a valuable tool to develop antiviral molecules that could act by blocking the virus entry in cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available